Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics senior vice president Patrick Plewman reported a mix of stock transactions and equity awards. On February 19, 2026, he completed an open‑market sale of 958 shares of common stock, leaving him with 15,838 shares held directly.
On February 18, 2026, he received a grant of 9,009 non-qualified stock options, which vest in three equal annual installments starting on the first anniversary of the grant date. He was also awarded 1,952 restricted stock units.
That same day, a total of 537 shares of common stock (244 shares at one price and 293 shares at another) were surrendered to the issuer solely to cover tax withholding obligations from vesting restricted stock units. The footnotes state the 958‑share sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted by Plewman.
Quest Diagnostics Executive Vice President and CFO Sam Sam reported several equity-related transactions. On February 18, 2026, he received a grant of 18,303 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also acquired 3,965 shares of common stock as an award of restricted stock units and disposed of 855 and 1,010 shares of common stock solely to cover tax withholding obligations arising from the vesting of restricted stock units, at prices of $210.01 and $206.99 per share. In addition, on January 28, 2026, he acquired 69 shares of common stock through a dividend reinvestment plan at $183.514 per share. Following these transactions, his directly held common stock position was reported as 27,841 shares, and he directly held 18,303 options.
Quest Diagnostics SVP & General Counsel Michael E. Prevoznik reported a mix of stock transactions. On February 19, 2026, he sold 1,111 shares of common stock in an open-market transaction at $204.83 per share, executed under a Rule 10b5-1 sales plan.
On February 18, 2026, he received a grant of 9,289 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant. He also acquired 2,013 shares of common stock as an award of restricted stock units, while 301 shares at $210.01 and 347 shares at $206.99 of common stock were surrendered to cover tax withholding from vesting. In addition, 5,738 shares are held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported equity compensation and related tax withholding transactions. Davis was granted 73,225 non-qualified stock options, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also received 15,857 shares of common stock, representing an award of restricted stock units. To cover tax withholding obligations arising from the vesting of restricted stock units, 2,396 shares and 3,788 shares of common stock were disposed of back to the issuer at prices of $210.01 and $206.99 per share, respectively. After these transactions, Davis directly owned 130,153 shares of common stock and 73,225 stock options.
Quest Diagnostics executive Catherine T. Doherty, EVP, Regional Businesses, reported multiple equity transactions. On February 19, 2026, she completed an open-market sale of 1,433 shares of common stock at $204.83 per share under a Rule 10b5-1 sales plan, leaving 68,402 directly held shares.
On February 18, 2026, she received a grant of 13,514 non-qualified stock options at an exercise price of $0.00 per option, vesting in three equal annual installments beginning on the first anniversary of the grant date. She also acquired 2,928 shares of common stock as a restricted stock unit award, with related tax-withholding dispositions of 433 shares at $210.01 and 728 shares at $206.99. In addition, 4,503 shares are held indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan.
Quest Diagnostics senior vice president Karthik Kuppusamy reported multiple equity-related transactions. He received a grant of 9,853 non-qualified stock options and an award of 2,135 restricted stock units, both at no cost. Shares of common stock totaling 252 and 259 were disposed of to the issuer solely to cover tax withholding obligations from vesting restricted stock units. He also recorded a small acquisition of 16 common shares under Rule 16a-6 and reported indirect holdings through a 401(k) plan and a trust. The granted options vest in three equal annual installments beginning on the first anniversary of the grant date.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported multiple equity-related transactions. On February 18, 2026, he was granted a non-qualified stock option for 7,332 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date. He also received 1,586 shares of common stock, which the footnotes describe as an award of restricted stock units. On the same date, 205 shares at $210.01 and 230 shares at $206.99 of common stock were disposed of back to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Separately, on January 28, 2026, he acquired 15 shares of common stock through a dividend reinvestment plan, which the rules allow to be reported later on Form 5 but he chose to report on this Form 4.
Quest Diagnostics SVP and Chief Accounting Officer Michael J. Deppe reported a mix of equity grants and related tax share withholdings. On February 18, 2026, he was granted a non‑qualified stock option covering 1,688 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date.
He also received an award of 366 restricted stock units. To cover tax withholding from vesting RSUs, 83 shares of common stock at $210.01 and 99 shares at $206.99 were disposed of to the issuer. After these transactions, he directly owns 34,560 shares of common stock and holds 1,688 options, plus an additional 706 shares indirectly through the company’s 401(k) plan.
Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share. The filing states these shares were obtained through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, but were reported early on Form 4. Following this small acquisition, his directly held position increased to 9,057 shares, a figure that includes shares previously acquired via dividend reinvestment since his last Form 4 filing.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.